Business Wire

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer — study results reported Monday that the drug’s makers AstraZeneca and Daiichi Sankyo believe could change the way the disease is treated for the first time in a decade. 

Oncologists agree, and noted with astonishment that the efficacy of Enhertu and other drugs used to treat HER2-positive breast cancer can now be measured in years. The progress has opened up the possibility of different ways of using these drugs, perhaps even for a limited duration, to improve patients’ quality of life and reduce financial burdens, while maintaining their benefits. 

advertisement

“This is a pivotal advancement for the treatment of HER2-positive metastatic breast cancer,” said Rebecca Dent, an oncologist and breast cancer specialist at the National Cancer Center in Singapore.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe